BCR-ABL minor (p190) RNA Quantitation

BCR-ABL minor (p190) RNA Quantitation

Oncology

Regulatory Status: CE-IVD, LDT

Quantitation of BCR-ABL Minor fusion gene transcripts (e1a2) by qPCR from peripheral blood.

 

Chronic Myeloid Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) is a myeloproliferative neoplasm characterized by a balanced genetic translocation between the Abelson (ABL) oncogene on chromosome 9 and breakpoint cluster region (BCR) on chromosome 22 t(9;22)(q34;q11). The deriving shorter chromosome 22 is termed the Philadelphia chromosome with a chimeric BCR-ABL gene that varies in size, depending on the breakpoint in the BCR gene. Patients with BCR-ABL minor breakpoint translocation are diagnosed by the formation of BCR-ABL fusion gene e1a2 that encode for a p190 protein via breakpoint occurring at exon 1 (e1) with second exon of ABL gene (a2). The encoded p190 protein has an elevated tyrosine kinase activity that is implicated with the pathogenesis of the disease1.

Reference:

1) Pane F, Intrieri M, Quintarelli C, Izzo B, Muccioli GC, Salvatore F. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene 21. 2002;8652–67.